Polaris Partners Closes Seventh Fund at $450M

Venture capital firm Polaris Partners closed its seventh fund at $450m.

Polaris Partners VII focuses on investing in building technology and healthcare companies.

Based in Boston, San Francisco and Dublin, Ireland, Polaris currently has Adimab, Art.com, BIND Therapeutics, Cardlytics, Focus Financial, JibJab, LegalZoom, Living Proof, Ocular Therapeutix, Receptos, WikiCell, and Quantcast in its portfolio. Exits include Alnylam Pharmaceuticals (ALNY; IPO 2004); Momenta (MNTA; IPO 2004); LogMeIn (LOGM; IPO 2009); Ironwood Pharmaceuticals (IRWD; IPO: 2010); ); Avila (acquired by Celgene; 2012); CodeRyte (acquired by 3M Corporation; 2012); Ascend Health (acquired by Universal Health Services; 2012); MarkMonitor (acquired by Thomson Reuters; 2012); Bridgepoint Medical (acquired by Boston Scientific; 2012); deCODE Genetics (acquired by Amgen; 2012).

The team members are listed on the firm’s web site here.



Join the discussion